Last reviewed · How we verify
NCT04982042: COVID19REHAB
Post COVID-19 Pulmonary Rehabilitation Program
NA trial testing Pulmonary Rehabilitation in Covid19 in 40 participants. Status unknown.
30 December 2021
Quick facts
| Lead sponsor | Centro Universitário de Anapolis |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 March 2021 |
| Primary completion | 30 December 2021 |
| Estimated completion | 30 July 2022 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Pulmonary Rehabilitation
Conditions studied
- Covid19 — all drugs for Covid19 →
- COVID-19 Respiratory Infection — all drugs for COVID-19 Respiratory Infection →
- Lung Diseases — all drugs for Lung Diseases →
- Respiratory Insufficiency — all drugs for Respiratory Insufficiency →
Sponsor
Centro Universitário de Anapolis
Who can join
16 and older, any sex, with Covid19 or COVID-19 Respiratory Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Coronavirus-2019 disease (COVID-19) is a highly infectious respiratory disease that causes respiratory, physical and psychological dysfunction in patients. With the increased understanding of the severity of COVID-19 and clinical evidence in accordance with the opinions of first-line clinical experts involved in the treatment of this epidemic, the investigators believe that the participation of patients with sequelae of COVID-19 in a Pulmonary Rehabilitation Program would be of utmost importance. According to recent scientific recommendations for patients with sequelae of COVID-19, respiratory rehabilitation would alleviate symptoms of dyspnea, anxiety and depression and, eventually, improve physical functions and quality of life. Therefore, it is essential to anticipate early rehabilitation after the acute phase of ARDS, in order to limit the severity of the effects of the ICU and promote rapid functional recovery. Physiotherapy will play a role in providing exercise, mobilization and rehabilitation interventions for survivors of critical illnesses associated with COVID-19, in order to enable a functional social return.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Health-Related Quality of Life and Functional Status of Post-COVID-19 Patients.
Oliveira MC, Alves LR, Soares JMP, Souza SKA, et al · · 2025 · cited 2× · PMID 40238313 · DOI 10.3390/ijerph22030338 -
Pulmonary Rehabilitation Program Is an Effective Treatment Approach for Post-COVID-19 Syndrome Patients.
Pádua K, Rosa KYA, Leal S, Oliveira Silva I, et al · · 2024 · PMID 39337028 · DOI 10.3390/jcm13185542 -
Outpatient and Home Pulmonary Rehabilitation Program Post COVID-19: A study protocol for clinical trial
Oliveira LVF, Oliveira MC, Lino MEM, Carrijo MM, et al · · 2022 · DOI 10.1101/2022.04.08.22273608
Verify or expand the search:
- PubMed search for NCT04982042
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pulmonary Rehabilitation
Trials testing the same drug.
- NCT07197229 — Hospital- and Home-Based Structured Pulmonary Rehabilitation in Recently Admitted COPD Patients: A Quasi-Experimental St · NA · not yet recruiting
- NCT07376161 — Inflammation and Oxidative Stress in COPD · enrolling by invitation
- NCT07097961 — Paediatric Post-TB Pulmonary Rehab Study · NA · recruiting
- NCT06756230 — Downhill Walking in IPF · NA · recruiting
- NCT06707623 — CPET Guided Rehab vs Physiotherapy in Patients With Dysfunctional Breathing · NA · recruiting
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other Centro Universitário de Anapolis trials
Trials by the same sponsor.
- NCT05516693 — Chewing, Swallowing and Orofacial Motricity in Severe Obese · NA · unknown
- NCT04545034 — Water Aerobics Session on Blood Pressure of Hypertensive Elderly. · NA · unknown
- NCT02390193 — Effect of Hemodialysis on Upper Airways Collapsibility in Patients With Chronic Kidney Disease · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04982042 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centro Universitário de Anapolis
- Last refreshed: 4 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04982042.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing